Sixty-six patients with chronic myelogenous leukemia, all with Philadelphia chromosome, have been studied for chromosomic abnormalities associated (CAA) to Ph', as well as for actuarial curve of survivorship. Patients dying from another disease were excluded from this study. Frequency of cells with CAA was measured and appeared strongly higher after blastic transformation than during myelocytic state; probability to be a blastic transformation is closely correlated with this frequency. On the other hand, actuarial curve of survivorship is very well represented by an exponential curve. This suggests a constant rate of death during disease evolution, for these patients without intercurrent disease. As a mean survivance after blastic transformation is very shorter than myelocytic duration, a constant rate of blastic transformation could be advanced: it explains possible occurrence of transformation as soon as preclinic state of a chronic myelogenous leukemia. Even if CAA frequency increases after blastic transformation, CAA can occur a long time before it and do not explain it: submicroscopic origin should be searched for the constant rate of blastic transformation would express the risk of a genic transformation at a constant rate during myelocytic state.

Download full-text PDF

Source

Publication Analysis

Top Keywords

blastic transformation
28
constant rate
16
transformation
9
abnormalities associated
8
chronic myelogenous
8
myelogenous leukemia
8
actuarial curve
8
curve survivorship
8
myelocytic state
8
rate blastic
8

Similar Publications

Article Synopsis
  • Chronic myelomonocytic leukemia (CMML) is a complex blood cell disorder that combines poorly functioning and overproducing blood cells, leading to various symptoms.
  • The case study focuses on a 71-year-old man with severe CMML who experienced skin nodules that improved with treatment but later recurred, while avoiding progression to acute leukemia.
  • The findings emphasize the importance of close monitoring and flexible treatment approaches for patients with CMML, especially those with skin involvement.
View Article and Find Full Text PDF

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia.

Cancers (Basel)

October 2024

Office of Oncologic Diseases, Center for Drug Evaluation and Research-CDER, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

Myeloid blast-phase chronic myeloid leukemia (MBP-CML) is a rare disease with a dismal prognosis. It is twice as common as lymphoid blast-phase CML, and its prognosis is poorer. Despite the success with tyrosine kinase inhibitors in the treatment of chronic-phase CML, the same does not hold true for MBP-CML.

View Article and Find Full Text PDF

MYB fusions are recurrently found in select cancers, including blastic plasmacytoid DC neoplasm (BPDCN), an acute leukemia with poor prognosis. They are markedly enriched in BPDCN compared with other blood cancers and, in some patients, are the only obvious somatic mutation detected. This suggests that they may alone be sufficient to drive DC transformation.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic myeloid leukemia (CML) can develop from a chronic phase to a rare megakaryoblastic phase, which has a poor prognosis and resistance to standard treatments like tyrosine kinase inhibitors (TKIs).
  • A case study details a 39-year-old woman whose CML progressed to this rare phase despite receiving chemotherapy, leading to her death within a month.
  • The diagnosis included various tests showing that the disease transformed into acute megakaryoblastic leukemia (AMKL), emphasizing the importance of using megakaryocytic markers in diagnosis for better treatment outcomes.
View Article and Find Full Text PDF

Chronic myelomonocytic leukemia is a clonal hematological disorder with an inherent risk of transformation to acute myeloid leukemia. Recently, there has been exponential discovery of molecular abnormalities in patients with chronic myelomonocytic leukemia. Some of these mutations independently contribute to a higher risk of transformation and result in inferior overall survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!